H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

April 6, 2026 6:53 AM

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found